Research Article
miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid
Table 4
Relative expression levels of serum miR-1291 within the different subgroups of bullous pemphigoid (BP) patients.
| Subgroups | | miR-1291 (2-ΔCt), median (IQR) | value |
| Sex | | | | Female | 20 | 0.52 (0.15-1.09) | 0.093 | Male | 25 | 0.25 (0.09-0.71) | Hypertension | | | | With | 14 | 0.30 (0.12-0.55) | 0.520 | Without | 31 | 0.31 (0.11-1.01) | Cerebrovascular disease | | | | With | 11 | 0.18 (0.08-0.63) | 0.255 | Without | 34 | 0.34 (0.15-1.02) | Mucosal involvement | | | | With | 10 | 0.45 (0.15-1.02) | 0.677 | Without | 35 | 0.31 (0.11-0.88) | CCL17 | | | | ≤549.0 pg/mL | 12 | 0.13 (0.08-0.24) | 0.009 | >549.0 pg/mL | 33 | 0.52 (0.16-1.03) | Anti-BP180 | | | | 0-9 U/mL | 7 | 0.63 (0.08-1.05) | 0.915 | >9 U/mL | 38 | 0.30 (0.14-0.81) | Anti-BP230 | | | | 0-9 U/mL | 20 | 0.23 (0.09-0.70) | 0.113 | >9 U/mL | 25 | 0.63 (0.15-1.09) |
|
|